Beone Medicines revenue and financials
Secondary listing. The primary listing is BeOne Medicines · NASDAQ (USD)
$217.00Change from previous close: −1.63%Absolute change: −$3.60
In the fiscal year ended December 2025, Beone Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total assets | 9,176 | 8,554 | 8,189 | 7,633 | 6,298 |
| Current assets | 7,216 | 6,601 | 6,234 | 5,664 | 4,310 |
| Cash and equivalents | 5,098 | 4,792 | 4,548 | 4,037 | 2,756 |
| Receivables | 1,071 | 948 | 887 | 902 | 880 |
| Inventory | 733 | 682 | 608 | 532 | 503 |
| Net property, plant and equipment | 1,794 | 1,789 | 1,716 | 1,771 | 1,766 |
| Other intangible assets | 61.0 | 61.7 | 142 | 63.6 | 64.9 |
| Long-term investments | 66.1 | 66.0 | 61.7 | 101 | 119 |
| Current liabilities | 2,119 | 1,812 | 1,829 | 2,368 | 2,210 |
| Accounts payable | 470 | 424 | 479 | 384 | 361 |
| Long-term debt | 882 | 963 | 962 | 140 | 146 |
| Total debt | 1,143 | 1,149 | 1,093 | 1,020 | 1,026 |
| Total liabilities | 4,002 | 3,793 | 3,827 | 3,503 | 2,528 |
| Total equity (incl. minority) | 5,174 | 4,760 | 4,361 | 4,129 | 3,770 |
| Retained earnings | -7,856 | -8,093 | -8,320 | -8,386 | -8,511 |